Introduction
Acute myeloid leukemia (AML) in the elderly is often characterized by adverse karyotypic and phenotypic features in a host who usually has a reduced ability to tolerate aggressive treatment regimens. Aggressive chemotherapy regimens are often associated with unacceptable rates of toxic deaths of up to 50% [1] . Therefore, polychemotherapy is still an issue of controversy in elderly patients with AML. First-line treatment in adult AML usually consists of ara-C and an anthracycline [2, 3] . The newer class II anthracycline aclarubicin (ACR) has been reported to be less cardiotoxic than doxo-and daunorubicin [4] but at least as effective as daunorubicin [5] . Furthermore, there appears to be no cross-resistance between ACR and other anthracyclines, since ACR inhibits RNA synthesis more efficiently than DNA synthesis and independently of P-glycoprotein overexpression and alteration of Topoisomerase II [6] . Etoposide has demonstrated interesting activity in older AML patients [7] , so we analysed the efficacy and toxicity of the combination of aclarubicin, etoposide and ara-C, using moderate doses in elderly AML patients.
Patients and methods

Eligibility
Inclusion criteria were AML according to FAB criteria, no history of previous chemotherapy or radiotherapy for other malignancies, age >60 years, and absence of nonhematologic disorders regarded as absolute contraindication for aggressive chemotherapy. All eligible patients referred to our institution between April 1991 and October 1993 were enrolled into the study. All patients gave their informed consent before treatment was started.
Therapy
Remission induction chemotherapy (AVA-7)
First induction chemotherapy consisted of aclarubicin 25 mg/m 2 /d as 30 min i.v. infusion for four days, etoposide 100 mg/m 2 /d as 30 min i.v. infusion for three days and ara-C 100 mg/m 2 /d as continuous i.v. infusion for three days and given i.v. within 30 min twice daily for an additional four days (AVA-7). All patients achieving CR or PR (PR = bone marrow blasts 5%-20%) were reinduced with a second course after recovery from bone marrow hypoplasia.
Consolidation therapy (A VA-5)
Patients in continuous CR after three months received a consolidation course consisting of the same dose schedule described above except for the omission in the last two days of ara-C (AVA-5).
Hematopoietic growth factors were not routinely used during the hypoplastic phase.
Remission criteria
The definition of CR by the CALGB was applied for the evaluation of treatment outcome. Partial remission was considered if bone marrow myeloblasts were reduced between 5% and 20% and hematopoiesis was reestablished after induction therapy.
Statistical evaluation
Continuous variables were analysed by unpaired /-test. All /"-values were two-tailed. Multiple comparisons of continuous variables were made by one-way ANOVA using Bonferroni correction. Duration of disease free survival (DFS) was determined from date of CR to leukemic relapse or death, and overall survival from the start of induction therapy. Survival curves were calculated as described by Kaplan and Meier, and differences were assessed by the log-rank test. Values are median if applicable (range). MDS = myelodysplastic syndrome; PCV = polycythemia rubra vera.
Results
Patient characteristics/toxicity
Patient characteristics are shown in Table 1 . The hematological toxicity was significantly higher during the first induction therapy than during the second induction and consolidation therapy. Non-hematological toxicity such as stomatitis, nausea, vomiting, and diarrhoea, was frequently encountered during all therapy courses, especially during first induction, but it rarely exceeded WHO grades 1-2. Only diarrhoea WHO grade 3 was seen in 34% of patients during first induction therapy. No significant cardiac toxic effects were observed. A mild-tomoderate skin reaction to aclarubicin (WHO grade 1-2) was seen in three cases. Early death occurred in four patients (12%) due to bacterial septicemia (n = 3) or fatal cerebral hemorrhage (n = 1) during first induction therapy-induced hypoplasia. One patient died in CR during hypoplasia after AVA-5 due to systemic fungal infection. Thus, the overall toxic death rate was 16% (five of 32 patients) after 63 courses of AVA-7/AVA-5.
Clinical response
After first induction therapy 14 patients (44%) achieved CR and 5 patients (16%) PR. Nine patients (28%) were primary non-responders. Two of the 19 patients who achieved CR or PR refused to continue with the second induction therapy. After 1-2 courses of AVA-7 a total of 17 patients (53%) achieved CR and two remained in PR (6%), for an overall response rate of 59%. Fourteen of 17 patients were consolidated with AVA-5 after three months in CR.
Duration of remission and survival
At a median follow-up time of 15.3 months (0.5^43.2 months) 15 of 17 patients in CR relapsed within two years. Two patients have been in continuous CR for 16+ and 29+ months, respectively. The median disease-free survival of all of the 17 patients in CR was one year, and the median survival of all 32 patients was 16.6 months (72 weeks). The median survival was 17.6 months (76 weeks) in patients who achieved CR or PR (« = 19), significantly longer than the two months (nine weeks) for those with resistant leukemia (P -0.02, log-rank test) (Figure 1 ). Univariate analysis identified no prognostic factor as predictive of response or survival.
Discussion
The CR rate of 53% and overall response rate of 59% found in our study compares favourably to those of many studies [2, 3, 5, [8] [9] [10] . Intensive polychemotherapy in elderly AML patients was frequently associated with high toxic death rates, ranging up to 50% [1] 17%) [9] , the overall treatment-related death rate of 16% in our study suggests that high CR rates achieved by intensive polychemotherapy are not necessarily associated with a high toxic death rate. The attenuated dose of aclarubicin of 25 mg/m 2 /d over four days caused no significant cardiotoxicity, in contrast to other studies in which the daily dose of aclarubicin ranged from 50 to 75 mg/m 2 [5] . Dose intensity in elderly patients with AML is still a matter of discussion. Despite the trial by Biichner et al. [2] , which showed a significantly higher CR rate (39%) after the first therapy course in the full-dose daunorubicin arm as compared to that of the attenuated-dose arm (21%), little correlation was found between dose intensity, CR rate and hypoplastic death rate in other trials [9, 10] . Only for high-dose ara-C (ara-C Ss 1 g/m 2 per single dose) was a clear lack of benefit demonstrated for elderly patients [8] .
The favourable overall and disease-free survival in this series as compared to that of other trials [9, 10] may be due to selection of patients and to the fact that some patients with resistant or relapsed disease responded to second-line treatment. Nevertheless, to have only two patients (12%) in continuous CR 16+ and 29+ months, respectively, is still an unsatisfactory result. The trial by Biichner et al. suggests that maintenance therapy for three years may be superior to intensive consolidation therapy in this age group, since long-term outcome was 24% after five years [2] . Thus, new approaches of consolidation and maintenance therapy for elderly AML patients have to be investigated in further studies.
Despite some encouraging results, it must also be considered that most studies of AML treatment in the elderly describe highly selected groups of patients [11] . The major clinical dilemma at this age is which patients are likely to achieve remission with intensive chemotherapy. First attempts to devise a prognostic scoring system [12] , which could prognosticate the patients likely to benefit from intensive therapy, still need to be validated.
